The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy

The anticancer efficacy of doxorubicin (DOX) is dose-limited because of cardiomyopathy, the most significant adverse effect. Initially, cardiotoxicity develops clinically silently, but it eventually appears as dilated cardiomyopathy with a very poor prognosis. Dexrazoxane (DEX) is the only FDA-appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Szponar, Jaroslaw, Ciechanski, Erwin, Ostrowska-Lesko, Marta, Gorska, Agnieszka, Tchorz, Michal, Dabrowska, Anna, Dudka, Jaroslaw, Murias, Marek, Kowalczyk, Michał, Korga-Plewko, Agnieszka, Mandziuk, Slawomir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298964/
https://www.ncbi.nlm.nih.gov/pubmed/37373350
http://dx.doi.org/10.3390/ijms241210202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298964/
https://www.ncbi.nlm.nih.gov/pubmed/37373350
http://dx.doi.org/10.3390/ijms241210202

Ejemplares similares